Hormonal Contraceptives Market Size, Share & Industry Analysis, By Product (Pills, Injectable, Vaginal Rings, Intrauterine Devices, Implants, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel, Public Channel & NGOs, and Others) and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Hormonal Contraceptives Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Hormonal Contraceptives market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Hormonal Contraceptives market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Hormonal Contraceptives Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Hormonal Contraceptives Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Hormonal Contraceptives Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Merck & Co., Inc & Bayer AG to Lead the Market
In terms of revenue, Merck & Co., Inc. accounts for a dominating position in the hormonal contraceptives market, owing to its two blockbuster products Nuvaring and Implanon/Nexplanon. Significant uptake of the two products across the globe is anticipated to boost the company growth during 2019-2026. Another prominent player operating in the market is Bayer AG, which markets contraceptive pills as well as a range of intrauterine devices. The Mirena range of products that contain 3 intrauterine devices generated a revenue of US$ 1,143 Mn in 2018, which propelled the hormonal contraceptive market growth of the company in 2018.

List Of Key Companies Covered:

  
Allergan
  
Merck & Co., Inc.
  
Janssen Pharmaceuticals, Inc.
  
Teva Pharmaceutical Industries
  
Pfizer, Inc.
  
Piramal Enterprises Ltd
  
Mylan N.V.
  
Novartis AG

REPORT COVERAGE

The ability of women to choose when and if to become pregnant has a significant impact on her well-being and health. It is highly important that various forms of contraception are widely accessible in every corner of the world, which is propelling the efforts taken by public & private players to promote family planning. Upsurge in the prevalence of sexually transmitted diseases and rising awareness about the infections such as HIV amongst the general population is propelling the hormonal contraceptives market growth.

The research report offers an in-depth analysis of the market. It further provides details on the fertility statistics, regulatory and reimbursement scenario for key countries, new product launches, and key industry developments such as mergers, acquisitions, and partnerships. Information on drivers, opportunities, threats, and restraints of the market can further help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players, along with their strategies, in the market.

Report Scope & Segmentation

 Segmentation

By Product

  
Pills
  
Injectable
  
Implants
  
Vaginal Ring
  
Intrauterine Devices
  
Others

By Distribution Channel

  
Hospital Pharmacy
  
Retail Pharmacy
  
Online Channel
  
Public Channel & NGOs
  
Others

By Geography

  
North America (the U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and the Rest of Latin America)
  
Middle East and Africa ( South Africa, GCC, and the Rest of Middle East & Africa)

INDUSTRY DEVELOPMENT:

October 2019: USFDA approved six-year duration for Liletta, a hormonal IUD manufactured by Allergan. The device is known to be the long-lasting and least-expensive approved hormonal IUD. Also, the IUD is available at the lowest Wholesale Acquisition Cost (WAC) of any IUD in the U.S

December 2019: Prasco Laboratories launched generic version of NuvaRing, the etonogestrel/ethinyl vaginal ring manufactured by Merck & Co., Inc.